Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manoceptâ„¢ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. The company, founded in 1983, maintains headquarters in Dublin, Ohio.
4100 Horizons Drive
Suite 205
Columbus, OH 43220
T: (614) 822-2322
investorrelations@navidea.com
Continental Stock Transfer & Trust Company
1 State Street
30th Floor
New York, NY 10004-1561
USA
T: 212-509-4000
cstmail@continentalstock.com
http://www.continentalstock.com